ストックスクリーナーアプリを入手
1.74
2.25%
-0.04
前日終値:
$1.78
開ける：
$1.8
24時間の取引高:
26,738
Relative Volume:
0.26
時価総額：
$3.08M
収益：
-
当期純損益:
$-10.91M
株価収益率:
-0.0219
EPS:
-79.5513
ネットキャッシュフロー:
$-12.14M
1週間 パフォーマンス:
-6.95%
1か月 パフォーマンス:
-24.68%
6か月 パフォーマンス:
-72.38%
1年 パフォーマンス:
-96.07%
1日の値動き範囲:
$1.695
$1.805
1週間の範囲:
$1.695
$1.86
52週間の値動き範囲:
$1.695
$80.36
Gri Bio Inc Stock (GRI) Company Profile
Compare GRI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.74 | 3.08M | 0 | -10.91M | -12.14M | -79.55 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-09 | 開始されました | H.C. Wainwright | Buy |
Gri Bio Inc (GRI) 最新ニュース
Price to earnings forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
Price to sales forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to revenue forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by over 76% as Pre-Revenue Biotech Continues Development - dars.gov.et
Enterprise value to EBIT forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
Price to earnings forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBIT forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBITDA forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
ADTX Stock Price and Chart — OTC:ADTX - TradingView
GRI Bio, Inc. Actuals & Estimates (NASDAQ:GRI) - TradingView
GRI Forecast — Price Target — Prediction for 2027 - TradingView
GRI Bio Inc. (GRI) Rallies 3.8% as Momentum Builds Above Key SupportBollinger Expansion - dars.gov.et
GRI Bio Inc (GRI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GRI Bio Inc (GRI) Institutional Confidence - TradingKey
GRI Bio Inc (GRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GRI Bio Secures FDA Orphan Drug Status for IPF - TipRanks
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
GRI Bio receives orphan drug status for IPF treatment - Investing.com
GRI Bio receives FDA orphan drug designation for IPF treatment - grafa.com
GRI Bio receives orphan drug status for IPF treatment By Investing.com - Investing.com Canada
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - GlobeNewswire
GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GRI Bio Inc (GRI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GRIGRI Bio Inc Forecast, Target Price - Finviz
GRI Q1 2026 Earnings: EPS Misses Estimates by 76% Amid Revenue AbsenceEarnings Per Share - lwvtexas.org
GRI Bio Inc. (GRI) Slips Over 5% as Stock Tests Key Support Near $1.90Median Line - newsline.com
GRI Q1 2026 Earnings: EPS Miss by 76% as Pre-Clinical Biotech Continues to Report No RevenueWeak Earnings Momentum - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses EstimatesLong-Term Guidance - newsline.com
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know - Benzinga
GRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Stepped-Up R&D SpendingROIC Trend Report - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses Estimates by 76%Dividend Increase Stocks - newsline.com
GRI Bio Inc. (GRI) Struggles Near Support Amid Mixed Technical SignalsVolume Gap - The Legal Advocate
GRI Bio Inc. (GRI) Posts Modest Gains as Stock Holds Above Key SupportWyckoff Spring - The Legal Advocate
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Company Faces HeadwindsEPS Consistency Score - The Legal Advocate
GRI Bio Inc. (GRI) Slides 7% as Shares Test Key Support at $1.96Relative Volume - Newser
GRI Bio (GRI) Q1 2026 Results Miss Estimates — EPS $-1.61 vs $-0.91Positive Surprise Momentum - Newser
GRI Bio CEO to discuss innovative immune therapies at healthcare showcase May 20 - Pluang
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase - GlobeNewswire
Number of shareholders of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Bio (GRI) Falls -5.56% — Watching $1.94 Support 2026-05-15Sector Rotation - Newser
GRI Bio Reports Positive Phase 2a Results for GRI-0621 in IPF and Advances Immune-Modulating Pipeline with Strong Q1 2026 Financials - Minichart
GRI Bio Highlights Promising Phase 2a IPF Data, Outlook - TipRanks
GRI Bio reports phase 2a data for IPF drug candidate GRI-0621 - Investing.com
GRI Bio Q1 net loss narrows on lower R&D expenses - TradingView
IPF Phase 2a results and cash runway update for GRI Bio (NASDAQ: GRI) - Stock Titan
GRI Bio Reports First Quarter 2026 Financial Results, New - GlobeNewswire
H.C. Wainwright Maintains GRI Bio(GRI.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Gri Bio Inc (GRI) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):